{"title": "SME Antibodies and Cancer Therapies: Building an Antibody-Targeted Drug Discovery Pipeline in Cancer Therapies: A Phase I Trial Using a Newest Efficacy Indicator for Cancer Clinical Trials", "authors": "Anne Buck Sarah Blackburn Danielle Wilson Frederick Beard Amy Norton", "published_date": "02-13-2016", "affiliation": "Arkansas State University-Main Campus, School of Environmental Studies", "text": "The molecular interactions and interactions of compounds exert a critical influence on their efficacy. And, many trials for therapy are based on histological reports of tumors. Such histological report can be problematic, as clinically binding compounds only respond to experimental treatment using antiretroviral drugs, while disease progression through cytotoxic therapy may be non-existent.<p>In this paper, the authors have extracted the 3-dimensional molecular features and connections in intracellular cancer cells as a basis for speculation in active therapeutic candidate development. Noveau patterns appear in nuclear DNA oxidation (NGE) inhibitors (inhibitors of NDE \u2013 which is one of the tools for cancer) with a dramatic effect on tumour growth. Because NGE-based inhibitors are expected to suppress expression of genes that cause cancer cells to cause oxidative cell death, these findings highlight the significance of active therapeutic candidate classification with molecule-level unstructured domains for protein expression compared to gene expression analysis and protein aggregation analysis. The authors have shown that all \u03b3 receptors (Th1, Th2) found in human cancer are candidates for therapy. The analysis of membrane and hematopoietic stem cells also have relevance for therapeutic candidate selection.<p>doi:10.1016/j.plans.2011.11.004<p>(For prospective/a phase I clinical trial using a peptide-based targeting agent, expect huge risk, significant money and potential of failure and read why. Also expect treatment failure and research abandonment.)<p>In fact, many untreated metastatic melanoma patients have metastases to the liver, where they require a liver transplant. However, currently available liver cancer cells with a high degree of oxidative stress are colonized with microRNAs for oxidative regulation, which is associated with higher resistance to irreversible patient relapse. This paper reminds us to seek just-so-slightly-different candidates for targeted therapy to keep liver cancer blood and in particular liver metastases under control.<p>References<p>Gayathri Chadalapaka, Seep Sreevalsan, Satya Pathi, Kyounghyun Kim, Cy Chen, Lisa Crose, Corinne Linardic, Stephen Safe, William D. Buckley, Pedrashli Mangadan, Laizo Poonkasapatigada, Joseph A. Kalt, Luke Kappes, Jonathon McDaniels, Ronald Vasilescu and Andrew Ring. Intra-cellular signature of cancer cells in OSL (Self-Activated Molecules in Recurrent Cancer Cells). Translational Research in OSL, Stand Alone and IPM/oncogenic therapies: The necessity for Intra cell Serum Signature Antibody System (IgSAS) in SP:MC2, Ip1 and Protulin-isp. Circulation, online 22 December 2011. doi:10.1016/j.plans.2011.11.004."}